Latest news with #Pharma
India.com
a day ago
- Business
- India.com
Meet woman, daughter of India's richest pharma tycoon, she now leads Rs 3950000000000 company, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is daughter of Dilip Shanghvi, a famous Pharma businessman. She is in headlines for her role in Sun Pharma, one of India's biggest pharmaceutical companies. His net worth is around $25 billion and known as India's richest pharma billionaire. He is also among the top 100 richest people in the world. But now, his daughter Vidhi Shanghvi has also started handling his business. Who Is Vidhi Shanghvi? Vidhi Shanghvi is an Executive Director in Sun Pharma. After 13 years of experience, she now leads Sun Pharma's Consumer Healthcare and India Distribution. Sun Pharma was founded by her father, Dilip Shanghvi in 1983. They started making psychiatric drugs and slowly became India's most valuable pharma company, with a market capitalisation of Rs 3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term. Vidhi Shanghvi Educational Background Vidhi graduated from the Wharton School at the University of Pennsylvania. In Sun Pharma, she used her education in marketing and consumer healthcare. She began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She also handled many marketing campaigns. After the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi became the Business Head of the company's Consumer Healthcare Division. She has played a big role in the growth of the products like Revital H and Volini in retail stores, pharmacies, and online platforms in India. She also has expertise in various fields like marketing, brand building, project and alliance management, and distribution. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform gives free, holistic mental health solutions to individuals for their mental well-being.
Yahoo
5 days ago
- Business
- Yahoo
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
Bristol Myers Squibb (BMY) closed at $48.66 in the latest trading session, marking a -2.19% move from the prior day. This change lagged the S&P 500's 0.94% gain on the day. At the same time, the Dow added 0.75%, and the tech-heavy Nasdaq gained 1.52%. Shares of the biopharmaceutical company witnessed a gain of 6.42% over the previous month, beating the performance of the Medical sector with its gain of 4.95%, and the S&P 500's gain of 1.67%. Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on July 31, 2025. It is anticipated that the company will report an EPS of $1.67, marking a 19.32% fall compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $11.32 billion, showing a 7.19% drop compared to the year-ago quarter. For the full year, the Zacks Consensus Estimates project earnings of $6.85 per share and a revenue of $46.31 billion, demonstrating changes of +495.65% and -4.11%, respectively, from the preceding year. Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.57% fall in the Zacks Consensus EPS estimate. At present, Bristol Myers Squibb boasts a Zacks Rank of #3 (Hold). In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.26. This represents a discount compared to its industry average Forward P/E of 19.72. We can also see that BMY currently has a PEG ratio of 1.45. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.45 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 32% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Hans India
6 days ago
- Business
- Hans India
Indicators show increased bearish momentum
Israel-Irantension rattled the equity market globally. The domestic market sharply declined on Friday. The Nifty was down by 284.45 points or 1.14 per cent. The BSE Sensex declined by 1.30 per cent. The Midcap-100 and Smallcap-100 slipped by 1.33 per cent and 1.12 per cent, respectively. On the sectoral front, Nifty IT is the top gainer with 3.15 per cent. The Pharma and Media indices are up by 1.39 per cent and 1.19 per cent, respectively. On the flip side, Realty is down by 3.13 per cent, and FMCG declined by 2.29 per cent. The Banknifty and FinNifty are down by 1.91 per cent and 1.86 per cent, respectively. Volatility index, India VIX is up by 3.08 per cent to 15.08. The FIIs sold Rs.4,812.39 crore and the DIIs bought Rs.44,150.72 crore worth of equities this month. The Nifty has formed a dark-cloud cover candlestick pattern on a weekly chart, which is a reversal sign. The index has been trading in the zone for the last four weeks. The breakout on Monday failed with a big bearish candle on Thursday. On Friday, it tested the support zone and recovered. Now, the 24473-24378 zone has become a lifeline support for the market. The Nifty closed below the 20 DMA decisively. Trading just 1.82 per cent below the 50 DMA. It is currently holding 8 distribution days. The 200DMA is also just 2.64 per cent away. The Bollinger bands were flattened. In any case, if the index declines below the 50 DMA with added distribution days, it will be negative, and the market will enter a confirmed downtrend. Since May 15th, the distribution volume has been high during the consolidation period. This suggests that the index may be forming a topping formation, following a massive over 15 per cent gain in just six weeks. The RSI is in a neutral zone on both weekly and daily charts. It formed a negative divergence on the weekly timeframe. If the daily RSI move below 50 (currently at 50.55), expect more downside risks. Even in the massive 15 per cent rise, the RSI has not shown greater momentum. The daily MACD shows an increased bearish momentum. The +DMI has formed a pivot and declined below the -DMI, which is an indication of a weaker trend. The Commodity Channel Index has already formed a top and is declining. In these conditions, for the resumption of an uptrend, the index must close above 25220 decisively, with fewer distribution days. Watch the 50 DMA of 24277 and the 200 DMA of 24082, which will act as crucial supports for now. In any case, a breakdown of consolidation and this support will be negative, and the market will enter into a decisive downtrend. The Geopolitical tensions and concerns about oil supply will be major risks now. India depends more on Iran's oil supplies. The crude oil prices will be negative on the inflation front. All the sectoral indices are losing momentum. The Nifty India Defence and IT indices outperformed last week. The IT index is improving its relative strength as well as momentum. Focus on this sector. Several Healthcare stocks are breaking out of a bases. The Midcap and Smallcap stocks may outperform the broader market. (The author is partner, Wealocity Analytics, Sebi-registered research analyst, chief mentor, Indus School of Technical Analysis, financial journalist, technical analyst and trainer)
Mint
7 days ago
- Business
- Mint
Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying ABB India, Godrej Properties shares tomorrow
Stock market news: Equity benchmark indices Sensex and Nifty 50 fell by nearly 1% on Friday, influenced by weak global markets and a surge in Brent crude oil prices following Israel's assault on Iran's capital, which dampened investor sentiment. Experiencing a decline for the second consecutive day, the 30-share BSE Sensex plummeted by 573.38 points or 0.70%, closing at 81,118.60. The Nifty 50 experienced a drop of 169.60 points or 0.68%, ending at 24,718.60. In terms of weekly performance, the BSE benchmark decreased by 1,070.39 points or 1.30%, while the Nifty 50 fell by 284.45 points or 1.13%. Investors were hesitant to engage with riskier assets due to concerns over a potential full-scale war between Israel and Iran, coupled with outflows from foreign funds. On the technical front, Dharmesh Shah, Vice President at ICICI Securities, expects Nifty 50 to hold 24,500 on a closing basis. Shah has recommended two stocks to buy for short-term. Here's what he expects from Indian stock market next week, along with his stock recommendation. Equity benchmark pared early week gains tracking subdued global cues owing to Israel's military strike on Iran. Consequently, Nifty 50 settled at 24,718, down 1.1%. Mirroring the benchmark move, Nifty midcap and small cap snapped 4 weeks winning streak, down 1.2%. Sectorally, profit booking was observed in recently rallied rate sensitives like, realty, financials and auto while IT, Pharma regained lost ground. The weekly price action formed a bear candle while sustaining above key support zone of 24,500, indicating extended breather. Brent crude oil jumped 18% during the week ($78) tracking escalated geopolitical tensions in the oil-rich Middle East. The risk-off sentiment fueled the momentum in safe heaven gold, up 3.5% at $3440. Going ahead, we expect volatility to remain elevated tracking geopolitical worries. Hence, development of geopolitical concern coupled with US Fed policy would have major bearing on the market which would dictate further course of action. Further, it is important to note that despite elevated volatility Nifty 50 managed to hold key support threshold of 24,500 and staged a rebound. Thereby, in the coming week, holding 24,500 on a closing basis would highlight strength and open the door for further pullback wherein immediate resistance is placed at 25,200. In the last four decades there have seen six major geopolitical escalations. On each occasion it formed major bottom once anxiety around the event settled down. Investing in such panic reactions with long term mind set has been rewarding as index has witnessed double digit returns in subsequent three months. In the current scenario, post the kneejerk reaction, we believe market would stabilise. Hence, we advise dips should be capitalised to build quality portfolios from medium to long term perspective. Structurally, the elongation of rallies followed by shallow correction is a perfect recipe of bull market. In current scenario, over past 21 sessions index has retraced merely 23.6% of preceding 25 sessions 16% up move. Slower pace of retracement indicating robust price structure that bodes well for next leg of up move. On the broader market front, Nifty midcap is undergoing healthy retracement after 28% rally which should be used as buying opportunity based on following observations: a) Since April low, Midcap index has not corrected >6% while on the weekly chart it has not closed below its previous week's low. In current scenario, despite ongoing volatility, midcap index has been maintaining the same rhythm. b) Further, the ratio chart of Nifty 500/Nifty 100 has been inching upward that clearly indicates relative outperformance. c) Improving market breadth as currently 55% of stock are trading above 200 days SMA compared to last month reading of 30%. Key monitorable which would provide cushion to the ongoing up move: a) Development of geopolitical concern c) Brent crude is poised at immediate hurdle of $78. Lack of follow through strength would result into consolidation in 78-66 levels d) Despite current decline, Index VIX is trading below immediate hurdle of 16 e) Further weakness in US Dollar index f) Bilateral Trade Agreement between India and US The key support threshold of 24,500 for the Nifty 50 is based on lower band of past four weeks consolidation coincided with 50% retracement of recent rally (23,935-25,222) and Friday's panic low is placed at 24,473. Dharmesh Shah of ICICI Securities recommends buying ABB India, and Godrej Properties shares this week. 1. Buy ABB India shares in the range of ₹ 5,950-6,130. He has ABB India share price target of ₹ 6,860 with a stop loss of ₹ 5,648. 2. Buy Godrej Properties shares in the range of ₹ 2,350-2,470. He has Godrej Properties share price target of ₹ 2,748 with a stop loss of ₹ 2,218. Disclaimer: The Research Analyst or his relatives or I-Sec do not have actual/beneficial ownership of 1% or more securities of the subject company, at the end of 13/06/2025 or have no other financial interest and do not have any material conflict of interest. The views and recommendations provided in this analysis are those of individual analysts or broking companies, not Mint. We strongly advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and individual circumstances may vary.
Business Standard
13-06-2025
- Business
- Business Standard
Natco Pharma's Mekaguda API unit completes USFDA inspection
NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active Pharmaceutical Ingredients (API) Unit The U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 9th June 13th June 2025. On conclusion of the inspection, the Company received 1 (One) observation in the Form-483. The Company believes that the observation is procedural in nature. The Company is confident to address this observation comprehensively.
